ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
ãã€ãªãã¯ãããžãŒ
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
ãã£ã³ã¬ã³ãžã®è©äŸ¡
ä»åŸã®ã€ãã³ã Mind Medicine Inc
ãã¹ãŠã®ã€ãã³ã
ä»åŸã®ã€ãã³ãã¯äºå®ãããŠããŸãã
èŠçŽåæ Mind Medicine Inc
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
売äžé«ãšçŽå©ç Mind Medicine Inc
ãã¹ãŠã®ãã©ã¡ãŒã¿
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
äœæ:
One World Trade Center, New York, NY, United States, 10007
äŒç€Ÿå:
Mind Medicine Inc
çºè¡è
ãã£ãã«ãŒ:
MNMD
ISIN:
CA60255C8850
åœ:
ã¢ã¡ãªã«åè¡åœ
亀æ:
NASDAQ
é貚:
$
äžå Žæ¥:
2020-03-03
ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
ãã€ãªãã¯ãããžãŒ
ãµã€ã:
https://www.mindmed.co
https://www.mindmed.co
